Denali Therapeutics (DNLI) Return on Equity: 2018-2024
Historic Return on Equity for Denali Therapeutics (DNLI) over the last 7 years, with Dec 2024 value amounting to -0.33%.
- Denali Therapeutics' Return on Equity rose 8.00% to -0.33% in Q4 2024 from the same period last year, while for Dec 2024 it was -0.33%, marking a year-over-year increase of 8.00%. This contributed to the annual value of -0.37% for FY2024, which is 23.00% down from last year.
- Latest data reveals that Denali Therapeutics reported Return on Equity of -0.33% as of Q4 2024, which was down 4.99% from -0.32% recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' Return on Equity ranged from a high of 0.07% in Q4 2020 and a low of -0.46% during Q1 2020.
- Its 3-year average for Return on Equity is -0.35%, with a median of -0.35% in 2022.
- Over the last 5 years, Denali Therapeutics' Return on Equity had its largest YoY gain of 54bps in 2020, and its largest YoY loss of 42bps in 2020.
- Over the past 5 years, Denali Therapeutics' Return on Equity (Quarterly) stood at 0.07% in 2020, then crashed by 36bps to -0.29% in 2021, then fell by 7bps to -0.36% in 2022, then declined by 5bps to -0.41% in 2023, then climbed by 8bps to -0.33% in 2024.
- Its Return on Equity was -0.33% in Q4 2024, compared to -0.32% in Q3 2024 and -0.30% in Q2 2024.